Table 1.
Characteristics of the study cohort
| Variable | Entire cohort | A−TN– | A+TN– | A+TN+ | A−TN+ | P value |
| Numbers (N) | 865 | 260 | 173 | 300 | 132 | |
| Age at bl, mean (SD) in years | 73 (7) | 71 (7) | 73 (7) | 74 (7) | 74 (8) | <0.001 * |
| Female no (%) | 399 (46) | 129 (50) | 62 (36) | 143 (48) | 65 (49) | 0.02* |
| Education, mean (SD) years | 16.3 (2.6) | 16.4 (2.6) | 16.5 (2.7) | 16 (2.7) | 16.3 (2.4) | 0.12* |
| APOE genotype positive, no (%) | 478 (55) | 211 (81) | 88 (51) | 88 (30) | 91 (69) | <0.001† |
| Plasma p-tau181 (pg/mL), mean (SD) | 19 (18) | 13 (9) | 17 (10) | 24 (11) | 20 (39) | <0.001* |
| Plasma NfL (pg/mL), mean (SD) | 39 (21) | 33 (19) | 38 (17) | 45 (19) | 40 (30) | <0.001* |
| CSF Aβ42 (pg/mL), mean (SD) | 1106 (607) | 1567 (396) | 665 (197) | 662 (166) | 1784 (641) | <0.001* |
| CSF t-tau (pg/ml), mean (SD) | 282 (131) | 191 (40) | 181 (44) | 389 (124) | 349 (106) | <0.001* |
| CSF p-tau181 (pg/mL), mean (SD) | 27 (14) | 17 (4) | 17 (5) | 39 (13) | 32 (11) | <0.001* |
| MMSE, score, mean (SD) | 27 (3) | 29 (2) | 28 (2) | 26 (3) | 28 (2) | <0.001* |
| ADNI-mem, score, mean (SD) | 0.4 (0.9) | 0.9 (0.7) | 0.4 (0.8) | −0.3 (0.9) | 0.7 (0.8) | <0.001* |
| CDR score, mean (SD) | 0.39 (0.32) | 0.28 (0.26) | 0.37 (0.29) | 0.55 (0.35) | 0.27 (0.29) | <0.001* |
*ANOVA.
†χ² test on independence.
Aβ, amyloid β; A+/−, amyloid-β positive/negative; ADNI, Alzheimer’s Disease Neuroimaging Initiative; ANOVA, analysis of variance; ATN, Aβ deposition, tau pathology and neurodegeneration; bl, baseline; CDR, clinical dementia rating; CSF, cerebrospinal fluid; mem, memory; MMSE, Mini-Mental State Examination; NfL, neurofilament light protein; p-tau181, plasma phosphorylated tau 181; sob, sum of boxes; TN+/−, tau/neurodegeneration positive/negative.